Company intelligence / Profile preview
Dompé
Milan, Italydompe.com ↗
- Ownership
- Private
- Employees
- ~800
- Development stage
- Commercial
01
Overview
Dompé has achieved commercial approval for cenegermin-bkbj/rhNGF in neurotrophic keratitis in the EU, US, and China. The company is advancing a broad pipeline targeting ophthalmology, immunology, respiratory diseases, and rare conditions. Notable clinical results include positive Phase II data for ladarixin in new-onset type 1 diabetes and reparixin in severe COVID‑19 pneumonia.
- Therapeutic areas
- PulmonologyOphthalmologyEndocrinologyInfectious Diseases
- Modalities
- Small moleculesRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
03
Partnerships
Engitix Therapeutics – strategic R&D collaboration using Exscalate platform for fibrosis/cancer drug discoveryAmgen – joint venture on oncology/nephrology drugsBiogen Idec – joint venture on multiple sclerosis therapies
Beyond the preview
Go deeper on Dompé.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dompé.